Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE
Philip J. Mease, Akihiko Asahina, Dafna D. Gladman, et al.
Lara D. Veeken (2022) Vol. 62, Iss. 2, pp. 617-628
Open Access | Times Cited: 11

Showing 11 citing articles:

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Yuxiong Jiang, Youdong Chen, Qian Yu, et al.
BioDrugs (2023) Vol. 37, Iss. 1, pp. 35-55
Open Access | Times Cited: 56
Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment
Bong-Woo Lee, Su‐Jin Moon
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11662-11662
Open Access | Times Cited: 31
Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies
Guillermo Sánchez-Rodríguez, L. Puig
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10305-10305
Open Access | Times Cited: 26
Pharmacologic Treatment Strategies in Psoriatic Arthritis
Gizem Ayan, André Lucas Ribeiro, Betul Macit, et al.
Clinical Therapeutics (2023) Vol. 45, Iss. 9, pp. 826-840
Open Access | Times Cited: 12
The Interleukine-17 Cytokine Family: Role in Development and Progression of Spondyloarthritis, Current and Potential Therapeutic Inhibitors
Anna Davydova, Yu. D. Kurochkina, Veronika E. Goncharova, et al.
Biomedicines (2023) Vol. 11, Iss. 5, pp. 1328-1328
Open Access | Times Cited: 5
Interleukin-17: A Putative Novel Pharmacological Target for Pathological Pain
Shao‐Jie Gao, Lin Liu, Danyang Li, et al.
Current Neuropharmacology (2023) Vol. 22, Iss. 2, pp. 204-216
Open Access | Times Cited: 4
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?
Flavia Sunzini, A. D’antonio, Mauro Fatica, et al.
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 12, pp. 1545-1559
Open Access | Times Cited: 7
Monotherapy or combination therapy in PsA: current aspects
Elpida Skouvaklidou, Paraskevi Avgerou, Konstantinos D Vassilakis, et al.
Therapeutic Advances in Musculoskeletal Disease (2024) Vol. 16
Open Access
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies
M. Elaine Husni, Philip J. Mease, Joseph F. Merola, et al.
RMD Open (2024) Vol. 10, Iss. 3, pp. e004464-e004464
Open Access
Bimekizumab safe and effective for AS and PsA in long-term trials
Robert Phillips
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 9, pp. 494-494
Closed Access | Times Cited: 2
Bimekizumab, a Humanized Monoclonal Immunoglobulin G1 Antibody for the Treatment of Psoriatic Arthritis: A Systematic Review
Ippei Miyagawa, Yoshiya Tanaka
touchREVIEWS in RMD (2023) Vol. 2, Iss. 1, pp. 11-11
Open Access
Page 1

Scroll to top